FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / The Potential of Mesenchymal Stem Cells to Treat Systemic In...
Frontiers in veterinary science2020; 6; 507; doi: 10.3389/fvets.2019.00507

The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.

Abstract: One hallmark of mesenchymal stem cells (MSCs) is the ability to differentiate into multiple tissue types which assists in tissue regeneration. Another hallmark of MSCs is their potent anti-inflammatory and immunomodulatory properties and the potential to treat inflammatory, immune-mediated, and ischemic conditions. In equine practice, MSCs have shown efficacy in the treatment of musculoskeletal disorders such as tendinopathy, meniscal tears and cartilage injury. However, there are many equine disease processes and conditions that may benefit from the immunomodulatory properties of MSCs. Examples include conditions associated with overwhelming acute inflammatory response such as systemic inflammatory response syndrome to chronic diseases characterized by a prolonged low level of inflammation such as equine asthma and recurrent uveitis. For the acute inflammatory response processes, there is often high morbidity and mortality with no effective immunomodulatory treatment to prevent the overwhelming synthesis of proinflammatory mediators. For chronic inflammatory disease processes, frequently long-term corticosteroid treatment is the therapeutic mainstay, with serious potential complications. Thus, there is an unmet need for alternative anti-inflammatory treatments for both acute and chronic illnesses in horses. While MSCs show promise for such conditions, much research is needed before a clinically safe and effective treatment will be available. Optimal MSC tissue source, patient vs. donor source (autologous vs. allogeneic) and cell growth conditions need to be determined for each problem. For immediate use, allogeneic MSC treatments is preferable, but immune tolerance and adequate safety require further study. MSC collection and cryopreservation from horses before they are injured or ill, whether from umbilical cord tissue, bone marrow or adipose might become more widespread. Once these fundamental approaches to treating specific diseases with MSCs are determined, the route of administration, dose and timing of administration also need to be studied. To provide a framework for development of MSC immunomodulatory treatments, this article reviews the current understanding of equine MSC anti-inflammatory and immunomodulatory properties and proposes how MSC therapy may be further developed to treat acute onset systemic inflammatory processes and chronic inflammatory diseases.
Copyright © 2020 MacDonald and Barrett.
Get Full Text
Publication Date: 2020-01-21 PubMed ID: 32039250PubMed Central: PMC6985200DOI: 10.3389/fvets.2019.00507Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This is a research exploration into the potential of Mesenchymal stem cells (MSCs) to treat both acute and chronic inflammatory conditions in horses, given their anti-inflammatory and immunomodulatory properties, and their role in tissue regeneration.

Mesenchymal Stem Cells (MSCs): A Potential Biomedical Solution

  • The study revolves around MSCs for their crucial role in tissue regeneration and their potent anti-inflammatory and immunomodulatory properties.
  • These cells hold promise in treating various inflammatory, immune-mediated, and ischemic conditions that affect horses.
  • MSCs have already shown enhanced efficacy in the treatment of musculoskeletal disorders such as tendinopathy, meniscal tears, and cartilage injury in equine practice.

Practical Application of MSCs in Equine Diseases

  • MSCs can be instrumental in treating various equine diseases that are associated with an acute inflammatory response like systemic inflammatory response syndrome, as well as chronic diseases linked with prolonged low-level inflammation like equine asthma and recurrent uveitis.
  • In most acute cases, there is a high rate of morbidity and mortality due to an excessive synthesis of proinflammatory mediators with no available immunomodulatory treatment.
  • Regarding chronic inflammatory diseases, long-term corticosteroid treatment is often employed, which might lead to serious complications, underlining the need for alternative anti-inflammatory treatments.

MSCs: Research Needs and Possible Approaches

  • While the therapeutic potential of MSCs is recognized, there is a need for extensive research to develop a clinically safe and effective treatment.
  • It is essential to determine an optimal MSC tissue source, consider deciding between patient vs. donor source (autologous vs. allogeneic), and understand the favorable cell growth conditions for each problem.
  • For immediate use, allogeneic MSC treatments seem to be preferable. However, their potential for immune tolerance and adequate safety still requires further exploration.
  • Future directions might include widespread collection and cryopreservation of MSCs from horses before they become injured or ill, possibly from umbilical cord tissue, bone marrow, or adipose.

Refining the Therapeutic Use of MSCs

  • Once these fundamental approaches are determined, the route of administration, dosage and timing of administering MSC treatment also need investigation and optimization.
  • This research provides a preliminary framework to plan further development of MSC immunomodulatory treatments, advancing the understanding of equine MSC anti-inflammatory and immunomodulatory properties.
  • Essentially, the study outlines how MSC therapy could be refined to treat acute onset systemic inflammatory processes and chronic inflammatory diseases effectively.

Cite This Article

APA
MacDonald ES, Barrett JG. (2020). The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses. Front Vet Sci, 6, 507. https://doi.org/10.3389/fvets.2019.00507

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 6
Pages: 507
PII: 507

Researcher Affiliations

MacDonald, Elizabeth S
  • Marion duPont Scott Equine Medical Center, Virginia Maryland College of Veterinary Medicine, Virginia Tech, Leesburg, VA, United States.
Barrett, Jennifer G
  • Marion duPont Scott Equine Medical Center, Virginia Maryland College of Veterinary Medicine, Virginia Tech, Leesburg, VA, United States.

References

This article includes 143 references
  1. Wang S, Zhao RC. A historical overview and concepts of mesenchymal stem cells. Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation Dordrecht: Springer; (2013). p. 3–15.
    doi: 10.1007/978-94-007-6716-4_1google scholar: lookup
  2. Burk J, Ribitsch I, Gittel C, Juelke H, Kasper C, Staszyk C, Brehm W. Growth and differentiation characteristics of equine mesenchymal stromal cells derived from different sources.. Vet J 2013 Jan;195(1):98-106.
    doi: 10.1016/j.tvjl.2012.06.004pubmed: 22841420google scholar: lookup
  3. Hoynowski SM, Fry MM, Gardner BM, Leming MT, Tucker JR, Black L, Sand T, Mitchell KE. Characterization and differentiation of equine umbilical cord-derived matrix cells.. Biochem Biophys Res Commun 2007 Oct 19;362(2):347-53.
    doi: 10.1016/j.bbrc.2007.07.182pubmed: 17719011google scholar: lookup
  4. Ranera B, Lyahyai J, Romero A, Vázquez FJ, Remacha AR, Bernal ML, Zaragoza P, Rodellar C, Martín-Burriel I. Immunophenotype and gene expression profiles of cell surface markers of mesenchymal stem cells derived from equine bone marrow and adipose tissue.. Vet Immunol Immunopathol 2011 Nov 15;144(1-2):147-54.
    doi: 10.1016/j.vetimm.2011.06.033pubmed: 21782255google scholar: lookup
  5. Barberini DJ, Freitas NP, Magnoni MS, Maia L, Listoni AJ, Heckler MC, Sudano MJ, Golim MA, da Cruz Landim-Alvarenga F, Amorim RM. Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential.. Stem Cell Res Ther 2014 Feb 21;5(1):25.
    doi: 10.1186/scrt414pmc: PMC4055040pubmed: 24559797google scholar: lookup
  6. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.. Cytotherapy 2006;8(4):315-7.
    doi: 10.1080/14653240600855905pubmed: 16923606google scholar: lookup
  7. Arnhold SJ, Goletz I, Klein H, Stumpf G, Beluche LA, Rohde C, Addicks K, Litzke LF. Isolation and characterization of bone marrow-derived equine mesenchymal stem cells.. Am J Vet Res 2007 Oct;68(10):1095-105.
    doi: 10.2460/ajvr.68.10.1095pubmed: 17916017google scholar: lookup
  8. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  9. de Mattos Carvalho A, Alves AL, Golim MA, Moroz A, Hussni CA, de Oliveira PG, Deffune E. Isolation and immunophenotypic characterization of mesenchymal stem cells derived from equine species adipose tissue.. Vet Immunol Immunopathol 2009 Dec 15;132(2-4):303-6.
    doi: 10.1016/j.vetimm.2009.06.014pubmed: 19647331google scholar: lookup
  10. De Schauwer C, Meyer E, Van de Walle GR, Van Soom A. Markers of stemness in equine mesenchymal stem cells: a plea for uniformity.. Theriogenology 2011 May;75(8):1431-43.
    doi: 10.1016/j.theriogenology.2010.11.008pubmed: 21196039google scholar: lookup
  11. Borjesson DL, Peroni JF. The regenerative medicine laboratory: facilitating stem cell therapy for equine disease.. Clin Lab Med 2011 Mar;31(1):109-23.
    doi: 10.1016/j.cll.2010.12.001pubmed: 21295725google scholar: lookup
  12. Fu Y, Karbaat L, Wu L, Leijten J, Both SK, Karperien M. Trophic Effects of Mesenchymal Stem Cells in Tissue Regeneration.. Tissue Eng Part B Rev 2017 Dec;23(6):515-528.
    doi: 10.1089/ten.teb.2016.0365pubmed: 28490258google scholar: lookup
  13. Carrade DD, Borjesson DL. Immunomodulation by mesenchymal stem cells in veterinary species.. Comp Med 2013 Jun;63(3):207-17.
    pmc: PMC3690426pubmed: 23759523
  14. Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases.. Autoimmun Rev 2011 May;10(7):410-5.
    doi: 10.1016/j.autrev.2011.01.005pubmed: 21256250google scholar: lookup
  15. Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response.. Immunol Lett 2015 Dec;168(2):140-6.
    doi: 10.1016/j.imlet.2015.05.004pubmed: 25982165google scholar: lookup
  16. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, Baan CC, Dahlke MH, Hoogduijn MJ. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion.. Front Immunol 2012;3:297.
    doi: 10.3389/fimmu.2012.00297pmc: PMC3458305pubmed: 23056000google scholar: lookup
  17. de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, Shankar AS, O'Flynn L, Elliman SJ, Roy D, Betjes MGH, Newsome PN, Baan CC, Hoogduijn MJ. Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells.. Stem Cells 2018 Apr;36(4):602-615.
    doi: 10.1002/stem.2779pubmed: 29341339google scholar: lookup
  18. Stewart MC, Stewart AA. Mesenchymal stem cells: characteristics, sources, and mechanisms of action.. Vet Clin North Am Equine Pract 2011 Aug;27(2):243-61.
    doi: 10.1016/j.cveq.2011.06.004pubmed: 21872757google scholar: lookup
  19. Barberini DJ, Aleman M, Aristizabal F, Spriet M, Clark KC, Walker NJ, Galuppo LD, Amorim RM, Woolard KD, Borjesson DL. Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.. Stem Cell Res Ther 2018 Apr 10;9(1):96.
    doi: 10.1186/s13287-018-0849-6pmc: PMC5891950pubmed: 29631634google scholar: lookup
  20. Sadan O, Melamed E, Offen D. Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.. Expert Opin Biol Ther 2009 Dec;9(12):1487-97.
    doi: 10.1517/14712590903321439pubmed: 19821796google scholar: lookup
  21. Kuraitis D, Ruel M, Suuronen EJ. Mesenchymal stem cells for cardiovascular regeneration.. Cardiovasc Drugs Ther 2011 Aug;25(4):349-62.
    doi: 10.1007/s10557-011-6311-ypubmed: 21637968google scholar: lookup
  22. Peroni JF, Borjesson DL. Anti-inflammatory and immunomodulatory activities of stem cells.. Vet Clin North Am Equine Pract 2011 Aug;27(2):351-62.
    doi: 10.1016/j.cveq.2011.06.003pubmed: 21872763google scholar: lookup
  23. Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F, Buerchler S, Friedman MS, Walker NJ, Borjesson DL. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses.. Cytotherapy 2011 Apr;13(4):419-30.
    doi: 10.3109/14653249.2010.536213pubmed: 21105841google scholar: lookup
  24. Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesenchymal stem cells in an inflamed joint environment.. Am J Vet Res 2017 Jul;78(7):867-875.
    doi: 10.2460/ajvr.78.7.867pubmed: 28650243google scholar: lookup
  25. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses.. Trends Immunol 2012 Mar;33(3):136-43.
    doi: 10.1016/j.it.2011.11.004pmc: PMC3412175pubmed: 22227317google scholar: lookup
  26. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation.. Annu Rev Pathol 2011;6:457-78.
    doi: 10.1146/annurev-pathol-011110-130230pubmed: 21073342google scholar: lookup
  27. Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells.. Transplantation 2009 May 15;87(9 Suppl):S45-9.
    doi: 10.1097/TP.0b013e3181a285b0pubmed: 19424005google scholar: lookup
  28. Lavoie JR, Rosu-Myles M. Uncovering the secretes of mesenchymal stem cells.. Biochimie 2013 Dec;95(12):2212-21.
    doi: 10.1016/j.biochi.2013.06.017pubmed: 23810910google scholar: lookup
  29. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources.. Cell Immunol 2010;264(2):171-9.
    doi: 10.1016/j.cellimm.2010.06.006pubmed: 20619400google scholar: lookup
  30. Ranera B, Antczak D, Miller D, Doroshenkova T, Ryan A, McIlwraith CW, Barry F. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.. Equine Vet J 2016 Mar;48(2):253-60.
    doi: 10.1111/evj.12414pubmed: 25582202google scholar: lookup
  31. Colbath AC, Dow SW, Phillips JN, McIlwraith CW, Goodrich LR. Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.. Stem Cells Dev 2017 Apr 1;26(7):503-511.
    doi: 10.1089/scd.2016.0266pubmed: 27958776google scholar: lookup
  32. Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. Mesenchymal stem cells stimulate antibody secretion in human B cells.. Scand J Immunol 2007 Apr;65(4):336-43.
    doi: 10.1111/j.1365-3083.2007.01905.xpubmed: 17386024google scholar: lookup
  33. Tabera S, Pérez-Simón JA, Díez-Campelo M, Sánchez-Abarca LI, Blanco B, López A, Benito A, Ocio E, Sánchez-Guijo FM, Cañizo C, San Miguel JF. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.. Haematologica 2008 Sep;93(9):1301-9.
    doi: 10.3324/haematol.12857pubmed: 18641017google scholar: lookup
  34. Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, Zhu X, Lu C, Liang W, Liao L, Zenke M, Zhao RC. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population.. Blood 2009 Jan 1;113(1):46-57.
    doi: 10.1182/blood-2008-04-154138pubmed: 18832657google scholar: lookup
  35. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  36. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells.. Cytokine Growth Factor Rev 2009 Oct-Dec;20(5-6):419-27.
    doi: 10.1016/j.cytogfr.2009.10.002pubmed: 19926330google scholar: lookup
  37. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism.. Am J Physiol Cell Physiol 2008 Mar;294(3):C675-82.
    doi: 10.1152/ajpcell.00437.2007pubmed: 18234850google scholar: lookup
  38. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD. Replicative senescence of mesenchymal stem cells: a continuous and organized process.. PLoS One 2008 May 21;3(5):e2213.
    doi: 10.1371/journal.pone.0002213pmc: PMC2374903pubmed: 18493317google scholar: lookup
  39. Cuerquis J, Romieu-Mourez R, François M, Routy JP, Young YK, Zhao J, Eliopoulos N. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation.. Cytotherapy 2014 Feb;16(2):191-202.
    doi: 10.1016/j.jcyt.2013.11.008pubmed: 24438900google scholar: lookup
  40. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Gosálvez J, Roy R, Zaragoza P, Martín-Burriel I, Rodellar C. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.. Stem Cells Dev 2017 Jan 1;26(1):15-24.
    doi: 10.1089/scd.2016.0209pubmed: 27712399google scholar: lookup
  41. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.. Vet Immunol Immunopathol 2016 Mar;171:57-65.
    doi: 10.1016/j.vetimm.2016.02.007pubmed: 26964718google scholar: lookup
  42. Cassano JM, Schnabel LV, Goodale MB, Fortier LA. The immunomodulatory function of equine MSCs is enhanced by priming through an inflammatory microenvironment or TLR3 ligand.. Vet Immunol Immunopathol 2018 Jan;195:33-39.
    doi: 10.1016/j.vetimm.2017.10.003pubmed: 29249315google scholar: lookup
  43. Cassano JM, Schnabel LV, Goodale MB, Fortier LA. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.. Stem Cell Res Ther 2018 Apr 3;9(1):82.
    doi: 10.1186/s13287-018-0840-2pmc: PMC5883371pubmed: 29615127google scholar: lookup
  44. Berglund AK, Fisher MB, Cameron KA, Poole EJ, Schnabel LV. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.. Front Vet Sci 2017;4:84.
    doi: 10.3389/fvets.2017.00084pmc: PMC5466990pubmed: 28660198google scholar: lookup
  45. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Inflammation affects the viability and plasticity of equine mesenchymal stem cells: possible implications in intra-articular treatments.. J Vet Sci 2017 Mar 30;18(1):39-49.
    doi: 10.4142/jvs.2017.18.1.39pmc: PMC5366301pubmed: 27297420google scholar: lookup
  46. Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source.. Stem Cells Dev 2014 Jun 1;23(11):1258-65.
    doi: 10.1089/scd.2013.0537pubmed: 24438346google scholar: lookup
  47. Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Møller K. Human endotoxemia as a model of systemic inflammation.. Curr Med Chem 2008;15(17):1697-705.
    doi: 10.2174/092986708784872393pubmed: 18673219google scholar: lookup
  48. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock.. Chest 1991 Jan;99(1):169-75.
    doi: 10.1378/chest.99.1.169pubmed: 1984950google scholar: lookup
  49. Thoefner MB, Ersbøll AK, Jensen AL, Hesselholt M. Factor analysis of the interrelationships between clinical variables in horses with colic.. Prev Vet Med 2001 Feb 16;48(3):201-14.
    doi: 10.1016/S0167-5877(00)00193-8pubmed: 11182463google scholar: lookup
  50. Tinker MK, White NA, Lessard P, Thatcher CD, Pelzer KD, Davis B, Carmel DK. Prospective study of equine colic incidence and mortality.. Equine Vet J 1997 Nov;29(6):448-53.
    doi: 10.1111/j.2042-3306.1997.tb03157.xpubmed: 9413717google scholar: lookup
  51. Senior JM, Proudman CJ, Leuwer M, Carter SD. Plasma endotoxin in horses presented to an equine referral hospital: correlation to selected clinical parameters and outcomes.. Equine Vet J 2011 Sep;43(5):585-91.
    doi: 10.1111/j.2042-3306.2010.00328.xpubmed: 21496089google scholar: lookup
  52. Steverink PJ, Salden HJ, Sturk A, Klein WR, van der Velden MA, Németh F. Laboratory and clinical evaluation of a chromogenic endotoxin assay for horses with acute intestinal disorders.. Vet Q 1994 May;16 Suppl 2:S117-21.
    doi: 10.1080/01652176.1994.9694517pubmed: 7801503google scholar: lookup
  53. Barton MH. Endotoxemia. Robinson's Current Therapy in Equine Medicine St. Louis, MO: Elsevier; (2003). p. 104–8.
    doi: 10.1016/B978-0-7216-9540-2.50034-7google scholar: lookup
  54. MacKay RJ, Merritt AM, Zertuche JM, Whittington M, Skelley LA. Tumor necrosis factor activity in the circulation of horses given endotoxin.. Am J Vet Res 1991 Apr;52(4):533-8.
    pubmed: 2053720
  55. Jones S. Diseases of the Equine Alimentary Tract. Large Animal Internal Medicine 5th ed. St. Louis, MO: Elsevier; (2015). p. 638–842.
  56. Morris DD. Endotoxemia in horses. A review of cellular and humoral mediators involved in its pathogenesis.. J Vet Intern Med 1991 May-Jun;5(3):167-81.
    doi: 10.1111/j.1939-1676.1991.tb00944.xpubmed: 1920254google scholar: lookup
  57. Hunt JM, Edwards GB, Clarke KW. Incidence, diagnosis and treatment of postoperative complications in colic cases.. Equine Vet J 1986 Jul;18(4):264-70.
    doi: 10.1111/j.2042-3306.1986.tb03623.xpubmed: 3758002google scholar: lookup
  58. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, Rojas M. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice.. Am J Physiol Lung Cell Mol Physiol 2007 Jul;293(1):L131-41.
    doi: 10.1152/ajplung.00431.2006pubmed: 17416739google scholar: lookup
  59. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage.. Nat Rev Drug Discov 2005 Oct;4(10):854-65.
    doi: 10.1038/nrd1854pubmed: 16224456google scholar: lookup
  60. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.. Am J Respir Crit Care Med 2010 Oct 15;182(8):1047-57.
    doi: 10.1164/rccm.201001-0010OCpubmed: 20558630google scholar: lookup
  61. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis.. Gut 2009 Jul;58(7):929-39.
    doi: 10.1136/gut.2008.168534pubmed: 19136511google scholar: lookup
  62. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.. Nat Med 2009 Jan;15(1):42-9.
    doi: 10.1038/nm.1905pmc: PMC2706487pubmed: 19098906google scholar: lookup
  63. Harman RM, Yang S, He MK, Van de Walle GR. Antimicrobial peptides secreted by equine mesenchymal stromal cells inhibit the growth of bacteria commonly found in skin wounds.. Stem Cell Res Ther 2017 Jul 4;8(1):157.
    doi: 10.1186/s13287-017-0610-6pmc: PMC5496374pubmed: 28676123google scholar: lookup
  64. Johnson V, Webb T, Norman A, Coy J, Kurihara J, Regan D, Dow S. Activated Mesenchymal Stem Cells Interact with Antibiotics and Host Innate Immune Responses to Control Chronic Bacterial Infections.. Sci Rep 2017 Aug 29;7(1):9575.
    doi: 10.1038/s41598-017-08311-4pmc: PMC5575141pubmed: 28851894google scholar: lookup
  65. Lalu MM, Sullivan KJ, Mei SH, Moher D, Straus A, Fergusson DA, Stewart DJ, Jazi M, MacLeod M, Winston B, Marshall J, Hutton B, Walley KR, McIntyre L. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial.. Elife 2016 Nov 17;5.
    doi: 10.7554/eLife.17850.023pmc: PMC5153252pubmed: 27870924google scholar: lookup
  66. Le Burel S, Thepenier C, Boutin L, Lataillade JJ, Peltzer J. Effect of Mesenchymal Stromal Cells on T Cells in a Septic Context: Immunosuppression or Immunostimulation?. Stem Cells Dev 2017 Oct 15;26(20):1477-1489.
    doi: 10.1089/scd.2016.0184pubmed: 28747098google scholar: lookup
  67. McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, Marshall J, Dos Santos C, Walley KR, Winston BW, Schlosser K, Fergusson DA. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial.. Am J Respir Crit Care Med 2018 Feb 1;197(3):337-347.
    doi: 10.1164/rccm.201705-1006OCpubmed: 28960096google scholar: lookup
  68. Perlee D, van Vught LA, Scicluna BP, Maag A, Lutter R, Kemper EM, van 't Veer C, Punchard MA, González J, Richard MP, Dalemans W, Lombardo E, de Vos AF, van der Poll T. Intravenous Infusion of Human Adipose Mesenchymal Stem Cells Modifies the Host Response to Lipopolysaccharide in Humans: A Randomized, Single-Blind, Parallel Group, Placebo Controlled Trial.. Stem Cells 2018 Nov;36(11):1778-1788.
    doi: 10.1002/stem.2891pubmed: 30063804google scholar: lookup
  69. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment.. J Aerosol Med Pulm Drug Deliv 2010 Aug;23(4):243-52.
    doi: 10.1089/jamp.2009.0775pmc: PMC3133560pubmed: 20073554google scholar: lookup
  70. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome.. J Clin Invest 2012 Aug;122(8):2731-40.
    doi: 10.1172/JCI60331pmc: PMC3408735pubmed: 22850883google scholar: lookup
  71. Lakritz J, Wilson WD, Berry CR, Schrenzel MD, Carlson GP, Madigan JE. Bronchointerstitial pneumonia and respiratory distress in young horses: clinical, clinicopathologic, radiographic, and pathological findings in 23 cases (1984-1989).. J Vet Intern Med 1993 Sep-Oct;7(5):277-88.
    doi: 10.1111/j.1939-1676.1993.tb01020.xpubmed: 8263846google scholar: lookup
  72. Dunkel B. Diseases of the respiratory system. Large Animal Internal Medicine 5th ed. St. Louis, MO: Elsevier; (2015). p. 461–637.
  73. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice.. J Immunol 2007 Aug 1;179(3):1855-63.
    doi: 10.4049/jimmunol.179.3.1855pubmed: 17641052google scholar: lookup
  74. Yang KY, Shih HC, How CK, Chen CY, Hsu HS, Yang CW, Lee YC, Perng RP, Peng CH, Li HY, Chang CM, Mou CY, Chiou SH. IV delivery of induced pluripotent stem cells attenuates endotoxin-induced acute lung injury in mice.. Chest 2011 Nov;140(5):1243-1253.
    doi: 10.1378/chest.11-0539pubmed: 21835903google scholar: lookup
  75. Rojas M, Cárdenes N, Kocyildirim E, Tedrow JR, Cáceres E, Deans R, Ting A, Bermúdez C. Human adult bone marrow-derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress syndrome in sheep.. Stem Cell Res Ther 2014 Mar 26;5(2):42.
    doi: 10.1186/scrt430pmc: PMC4055116pubmed: 24670268google scholar: lookup
  76. Xiang B, Chen L, Wang X, Zhao Y, Wang Y, Xiang C. Transplantation of Menstrual Blood-Derived Mesenchymal Stem Cells Promotes the Repair of LPS-Induced Acute Lung Injury.. Int J Mol Sci 2017 Mar 27;18(4).
    doi: 10.3390/ijms18040689pmc: PMC5412275pubmed: 28346367google scholar: lookup
  77. Couëtil LL, Cardwell JM, Gerber V, Lavoie JP, Léguillette R, Richard EA. Inflammatory Airway Disease of Horses--Revised Consensus Statement.. J Vet Intern Med 2016 Mar-Apr;30(2):503-15.
    doi: 10.1111/jvim.13824pmc: PMC4913592pubmed: 26806374google scholar: lookup
  78. Léguillette R. Recurrent airway obstruction--heaves.. Vet Clin North Am Equine Pract 2003 Apr;19(1):63-86, vi.
    doi: 10.1016/S0749-0739(02)00067-6pubmed: 12747662google scholar: lookup
  79. Pirie RS. Recurrent airway obstruction: a review.. Equine Vet J 2014 May;46(3):276-88.
    doi: 10.1111/evj.12204pubmed: 24164473google scholar: lookup
  80. Horohov DW. Equine T-cell cytokines. Protection and pathology.. Vet Clin North Am Equine Pract 2000 Apr;16(1):1-14.
    doi: 10.1016/S0749-0739(17)30115-3pubmed: 10752135google scholar: lookup
  81. Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model.. Am J Physiol Lung Cell Mol Physiol 2010 Dec;299(6):L760-70.
    doi: 10.1152/ajplung.00182.2009pmc: PMC4116401pubmed: 20817776google scholar: lookup
  82. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG, Hodges MG, Jelinek I, Madala S, Karpati S, Mezey E. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma.. Proc Natl Acad Sci U S A 2010 Mar 23;107(12):5652-7.
    doi: 10.1073/pnas.0910720107pmc: PMC2851758pubmed: 20231466google scholar: lookup
  83. Urbanek K, De Angelis A, Spaziano G, Piegari E, Matteis M, Cappetta D, Esposito G, Russo R, Tartaglione G, De Palma R, Rossi F, D'Agostino B. Intratracheal Administration of Mesenchymal Stem Cells Modulates Tachykinin System, Suppresses Airway Remodeling and Reduces Airway Hyperresponsiveness in an Animal Model.. PLoS One 2016;11(7):e0158746.
    doi: 10.1371/journal.pone.0158746pmc: PMC4951036pubmed: 27434719google scholar: lookup
  84. Trzil JE, Masseau I, Webb TL, Chang CH, Dodam JR, Cohn LA, Liu H, Quimby JM, Dow SW, Reinero CR. Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma.. Clin Exp Allergy 2014 Dec;44(12):1546-57.
    doi: 10.1111/cea.12411pmc: PMC4247171pubmed: 25220646google scholar: lookup
  85. Trzil JE, Masseau I, Webb TL, Chang CH, Dodam JR, Liu H, Quimby JM, Dow SW, Reinero CR. Intravenous adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study.. J Feline Med Surg 2016 Dec;18(12):981-990.
    doi: 10.1177/1098612X15604351pubmed: 26384398google scholar: lookup
  86. Antunes MA, Lapa E Silva JR, Rocco PR. Mesenchymal stromal cell therapy in COPD: from bench to bedside.. Int J Chron Obstruct Pulmon Dis 2017;12:3017-3027.
    doi: 10.2147/COPD.S146671pmc: PMC5652911pubmed: 29081655google scholar: lookup
  87. Zucca E, Corsini E, Galbiati V, Lange-Consiglio A, Ferrucci F. Evaluation of amniotic mesenchymal cell derivatives on cytokine production in equine alveolar macrophages: an in vitro approach to lung inflammation.. Stem Cell Res Ther 2016 Sep 20;7(1):137.
    doi: 10.1186/s13287-016-0398-9pmc: PMC5028987pubmed: 27651133google scholar: lookup
  88. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.. Gut 2010 Dec;59(12):1662-9.
    doi: 10.1136/gut.2010.215152pubmed: 20921206google scholar: lookup
  89. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease.. Ann Intern Med 2005 Dec 20;143(12):895-904.
    doi: 10.7326/0003-4819-143-12-200512200-00007pubmed: 16365470google scholar: lookup
  90. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.. Gastroenterology 2011 May;140(6):1756-1767.
    doi: 10.1053/j.gastro.2011.02.016pmc: PMC3773507pubmed: 21530742google scholar: lookup
  91. Schumacher J, Edwards JF, Cohen ND. Chronic idiopathic inflammatory bowel diseases of the horse.. J Vet Intern Med 2000 May-Jun;14(3):258-65.
    doi: 10.1111/j.1939-1676.2000.tb01164.xpubmed: 10830538google scholar: lookup
  92. Kol A, Walker NJ, Nordstrom M, Borjesson DL. Th17 Pathway As a Target for Multipotent Stromal Cell Therapy in Dogs: Implications for Translational Research.. PLoS One 2016;11(2):e0148568.
    doi: 10.1371/journal.pone.0148568pmc: PMC4752288pubmed: 26872054google scholar: lookup
  93. Olofsson KM, Hjertner B, Fossum C, Press CM, Lindberg R. Expression of T helper type 17 (Th17)-associated cytokines and toll-like receptor 4 and their correlation with Foxp3 positive cells in rectal biopsies of horses with clinical signs of inflammatory bowel disease.. Vet J 2015 Oct;206(1):97-104.
    doi: 10.1016/j.tvjl.2015.07.003pubmed: 26346261google scholar: lookup
  94. Zimmermann K, Haas A, Oxenius A. Systemic antibody responses to gut microbes in health and disease.. Gut Microbes 2012 Jan-Feb;3(1):42-7.
    doi: 10.4161/gmic.19344pubmed: 22356852google scholar: lookup
  95. Soontararak S, Chow L, Johnson V, Coy J, Webb C, Wennogle S, Dow S. Humoral immune responses against gut bacteria in dogs with inflammatory bowel disease.. PLoS One 2019;14(8):e0220522.
    doi: 10.1371/journal.pone.0220522pmc: PMC6675102pubmed: 31369623google scholar: lookup
  96. Kol A, Foutouhi S, Walker NJ, Kong NT, Weimer BC, Borjesson DL. Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions.. Stem Cells Dev 2014 Aug 15;23(16):1831-43.
    doi: 10.1089/scd.2014.0128pmc: PMC4120524pubmed: 24803072google scholar: lookup
  97. Panés J, Ordás I, Ricart E. Stem cell treatment for Crohn's disease.. Expert Rev Clin Immunol 2010 Jul;6(4):597-605.
    doi: 10.1586/eci.10.27pubmed: 20594133google scholar: lookup
  98. Barr BS. Infiltrative intestinal disease.. Vet Clin North Am Equine Pract 2006 Apr;22(1):e1-7.
    doi: 10.1016/j.cveq.2005.12.030pubmed: 16627090google scholar: lookup
  99. Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, Benson TJ, Evans R. A scoring index for disease activity in canine inflammatory bowel disease.. J Vet Intern Med 2003 May-Jun;17(3):291-7.
    doi: 10.1111/j.1939-1676.2003.tb02450.xpubmed: 12774968google scholar: lookup
  100. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.. Gastroenterology 2009 Mar;136(3):978-89.
    doi: 10.1053/j.gastro.2008.11.041pubmed: 19135996google scholar: lookup
  101. Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D, Dow S. Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model.. Stem Cells Transl Med 2018 Jun;7(6):456-467.
    doi: 10.1002/sctm.17-0305pmc: PMC5980202pubmed: 29635868google scholar: lookup
  102. Webb TL, Webb CB. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study.. J Feline Med Surg 2015 Oct;17(10):901-8.
    doi: 10.1177/1098612X14561105pubmed: 25480816google scholar: lookup
  103. Pérez-Merino EM, Usón-Casaús JM, Zaragoza-Bayle C, Duque-Carrasco J, Mariñas-Pardo L, Hermida-Prieto M, Barrera-Chacón R, Gualtieri M. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Clinical and laboratory outcomes.. Vet J 2015 Dec;206(3):385-90.
    doi: 10.1016/j.tvjl.2015.08.003pubmed: 26526522google scholar: lookup
  104. Pérez-Merino EM, Usón-Casaús JM, Duque-Carrasco J, Zaragoza-Bayle C, Mariñas-Pardo L, Hermida-Prieto M, Vilafranca-Compte M, Barrera-Chacón R, Gualtieri M. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Endoscopic and histological outcomes.. Vet J 2015 Dec;206(3):391-7.
    doi: 10.1016/j.tvjl.2015.07.023pubmed: 26526521google scholar: lookup
  105. Chang Q, Yan L, Wang CZ, Zhang WH, Hu YZ, Wu BY. In vivo transplantation of bone marrow mesenchymal stem cells accelerates repair of injured gastric mucosa in rats.. Chin Med J (Engl) 2012 Mar;125(6):1169-74.
    pubmed: 22613549
  106. Gonçalves Fda C, Schneider N, Pinto FO, Meyer FS, Visioli F, Pfaffenseller B, Lopez PL, Passos EP, Cirne-Lima EO, Meurer L, Paz AH. Intravenous vs intraperitoneal mesenchymal stem cells administration: what is the best route for treating experimental colitis?. World J Gastroenterol 2014 Dec 28;20(48):18228-39.
    doi: 10.3748/wjg.v20.i48.18228pmc: PMC4277960pubmed: 25561790google scholar: lookup
  107. Wang N, Shao Y, Mei Y, Zhang L, Li Q, Li D, Shi S, Hong Q, Lin H, Chen X. Novel mechanism for mesenchymal stem cells in attenuating peritoneal adhesion: accumulating in the lung and secreting tumor necrosis factor α-stimulating gene-6.. Stem Cell Res Ther 2012 Dec 6;3(6):51.
    doi: 10.1186/scrt142pmc: PMC3580481pubmed: 23217986google scholar: lookup
  108. Gilger BC, Hollingsworth SR. Diseases of the uvea, uveitis, and recurrent uveitis. Equine Ophthalmology Hoboken, NJ: John Wiley & Sons, Inc; (2016). p. 369–415.
    doi: 10.1002/9781119047919.ch8google scholar: lookup
  109. Gilger BC, Malok E, Cutter KV, Stewart T, Horohov DW, Allen JB. Characterization of T-lymphocytes in the anterior uvea of eyes with chronic equine recurrent uveitis.. Vet Immunol Immunopathol 1999 Oct 1;71(1):17-28.
    doi: 10.1016/S0165-2427(99)00082-3pubmed: 10522783google scholar: lookup
  110. Regan DP, Aarnio MC, Davis WS, Carmichael KP, Vandenplas ML, Lauderdale JD, Moore PA. Characterization of cytokines associated with Th17 cells in the eyes of horses with recurrent uveitis.. Vet Ophthalmol 2012 May;15(3):145-52.
    doi: 10.1111/j.1463-5224.2011.00951.xpubmed: 22051225google scholar: lookup
  111. Gilger BC, Michau TM. Equine recurrent uveitis: new methods of management.. Vet Clin North Am Equine Pract 2004 Aug;20(2):417-27, vii.
    doi: 10.1016/j.cveq.2004.04.010pubmed: 15271431google scholar: lookup
  112. Zhang L, Zheng H, Shao H, Nian H, Zhang Y, Bai L, Su C, Liu X, Dong L, Li X, Zhang X. Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats.. Invest Ophthalmol Vis Sci 2014 Aug 14;55(9):5561-71.
    doi: 10.1167/iovs.14-14788pmc: PMC4580152pubmed: 25125599google scholar: lookup
  113. Dodi PL. Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management.. Vet Med (Auckl) 2015;6:341-347.
    doi: 10.2147/VMRR.S66705pmc: PMC6067592pubmed: 30101119google scholar: lookup
  114. Bittencourt MK, Barros MA, Martins JF, Vasconcellos JP, Morais BP, Pompeia C, Bittencourt MD, Evangelho KD, Kerkis I, Wenceslau CV. Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca.. Cell Med 2016 Dec 3;8(3):63-77.
    doi: 10.3727/215517916X693366pmc: PMC5165646pubmed: 28003932google scholar: lookup
  115. Brooks D, Matthews A, Clode AB. Diseases of the cornea. Equine Ophthalmology 3rd ed. Hoboken, NJ: Wiley; (2016). p. 252–368.
    doi: 10.1002/9781119047919.ch7google scholar: lookup
  116. Davis AB, Schnabel LV, Gilger BC. Subconjunctival bone marrow-derived mesenchymal stem cell therapy as a novel treatment alternative for equine immune-mediated keratitis: A case series.. Vet Ophthalmol 2019 Sep;22(5):674-682.
    doi: 10.1111/vop.12641pubmed: 30715781google scholar: lookup
  117. Marfe G, Massaro-Giordano M, Ranalli M, Cozzoli E, Di Stefano C, Malafoglia V, Polettini M, Gambacurta A. Blood derived stem cells: an ameliorative therapy in veterinary ophthalmology.. J Cell Physiol 2012 Mar;227(3):1250-6.
    doi: 10.1002/jcp.22953pubmed: 21792938google scholar: lookup
  118. Sherman AB, Gilger BC, Berglund AK, Schnabel LV. Effect of bone marrow-derived mesenchymal stem cells and stem cell supernatant on equine corneal wound healing in vitro.. Stem Cell Res Ther 2017 May 25;8(1):120.
    doi: 10.1186/s13287-017-0577-3pmc: PMC5445363pubmed: 28545510google scholar: lookup
  119. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice.. Blood 2005 Dec 15;106(13):4057-65.
    doi: 10.1182/blood-2005-03-1004pubmed: 16118325google scholar: lookup
  120. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.. Blood 2006 Sep 15;108(6):2114-20.
    doi: 10.1182/blood-2005-11-011650pmc: PMC1895546pubmed: 16690970google scholar: lookup
  121. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study.. Equine Vet J 2008 Mar;40(2):178-81.
    doi: 10.2746/042516408X276942pubmed: 18267891google scholar: lookup
  122. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  123. Ardanaz N, Vázquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, Ranera B, Vitoria A, Albareda J, Prades M, Zaragoza P, Martín-Burriel I, Rodellar C. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.. BMC Vet Res 2016 Mar 31;12:65.
    doi: 10.1186/s12917-016-0692-xpmc: PMC4815220pubmed: 27029614google scholar: lookup
  124. Ursini TL, Amelse LL, Elkhenany HA, Odoi A, Carter-Arnold JL, Adair HS, Dhar MS. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.. Equine Vet J 2019 Mar;51(2):198-205.
    doi: 10.1111/evj.12992pubmed: 29992618google scholar: lookup
  125. Carrade DD, Affolter VK, Outerbridge CA, Watson JL, Galuppo LD, Buerchler S, Kumar V, Walker NJ, Borjesson DL. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions.. Cytotherapy 2011 Nov;13(10):1180-92.
    doi: 10.3109/14653249.2011.602338pubmed: 21899391google scholar: lookup
  126. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  127. Broeckx S, Borena BM, Zimmerman M, Mariën T, Seys B, Suls M, Duchateau L, Spaas JH. Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.. Curr Stem Cell Res Ther 2014;9(6):452-7.
    doi: 10.2174/1574888X09666140220003847pubmed: 24548143google scholar: lookup
  128. Kol A, Wood JA, Carrade Holt DD, Gillette JA, Bohannon-Worsley LK, Puchalski SM, Walker NJ, Clark KC, Watson JL, Borjesson DL. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.. Stem Cell Res Ther 2015 Apr 15;6(1):73.
    doi: 10.1186/s13287-015-0050-0pmc: PMC4446064pubmed: 25888916google scholar: lookup
  129. Williams LB, Co C, Koenig JB, Tse C, Lindsay E, Koch TG. Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.. Front Vet Sci 2016;3:56.
    doi: 10.3389/fvets.2016.00056pmc: PMC4956649pubmed: 27500136google scholar: lookup
  130. Dias MC, Landim-Alvarenga FD, de Moraes CN, da Costa LD, Geraldini CM, de Vasconcelos Machado VM, Maia L. Intramuscular Transplantation of Allogeneic Mesenchymal Stromal Cells Derived from Equine Umbilical Cord.. Int J Stem Cells 2016 Nov 30;9(2):239-249.
    doi: 10.15283/ijsc16011pmc: PMC5155720pubmed: 27572709google scholar: lookup
  131. Owens SD, Kol A, Walker NJ, Borjesson DL. Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses.. Stem Cells Int 2016;2016:5830103.
    doi: 10.1155/2016/5830103pmc: PMC5018342pubmed: 27648075google scholar: lookup
  132. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  133. Barrachina L, Remacha AR, Romero A, Zaragoza P, Vázquez FJ, Rodellar C. Differentiation of equine bone marrow derived mesenchymal stem cells increases the expression of immunogenic genes.. Vet Immunol Immunopathol 2018 Jun;200:1-6.
    doi: 10.1016/j.vetimm.2018.04.004pubmed: 29776607google scholar: lookup
  134. Carter-Arnold JL, Neilsen NL, Amelse LL, Odoi A, Dhar MS. In vitro analysis of equine, bone marrow-derived mesenchymal stem cells demonstrates differences within age- and gender-matched horses.. Equine Vet J 2014 Sep;46(5):589-95.
    doi: 10.1111/evj.12142pubmed: 23855680google scholar: lookup
  135. Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies.. Stem Cell Res Ther 2013 Apr 30;4(2):48.
    doi: 10.1186/scrt198pmc: PMC3707049pubmed: 23632128google scholar: lookup
  136. Nam A, Han SM, Go DM, Kim DY, Seo KW, Youn HY. Long-Term Management with Adipose Tissue-Derived Mesenchymal Stem Cells and Conventional Treatment in a Dog with Hepatocutaneous Syndrome.. J Vet Intern Med 2017 Sep;31(5):1514-1519.
    doi: 10.1111/jvim.14798pmc: PMC5598886pubmed: 28782844google scholar: lookup
  137. Lohan P, Treacy O, Griffin MD, Ritter T, Ryan AE. Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?. Front Immunol 2017;8:1626.
    doi: 10.3389/fimmu.2017.01626pmc: PMC5705547pubmed: 29225601google scholar: lookup
  138. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.. Proc Natl Acad Sci U S A 2002 Jun 25;99(13):8932-7.
    doi: 10.1073/pnas.132252399pmc: PMC124401pubmed: 12084934google scholar: lookup
  139. Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients.. Haematologica 2007 Sep;92(9):1208-15.
    doi: 10.3324/haematol.11446pubmed: 17666368google scholar: lookup
  140. Clark KC, Kol A, Shahbenderian S, Granick JL, Walker NJ, Borjesson DL. Canine and Equine Mesenchymal Stem Cells Grown in Serum Free Media Have Altered Immunophenotype.. Stem Cell Rev Rep 2016 Apr;12(2):245-56.
    doi: 10.1007/s12015-015-9638-0pmc: PMC4841858pubmed: 26638159google scholar: lookup
  141. Schnabel LV, Fortier LA, McIlwraith CW, Nobert KM. Therapeutic use of stem cells in horses: which type, how, and when?. Vet J 2013 Sep;197(3):570-7.
    doi: 10.1016/j.tvjl.2013.04.018pubmed: 23778257google scholar: lookup
  142. van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, van Belle E, Gyöngyösi M, Sluijter JP, Cramer MJ, Doevendans PA, Chamuleau SA. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease.. Cardiovasc Res 2011 Sep 1;91(4):649-58.
    doi: 10.1093/cvr/cvr113pubmed: 21498423google scholar: lookup
  143. Cheng I, Park DY, Mayle RE, Githens M, Smith RL, Park HY, Hu SS, Alamin TF, Wood KB, Kharazi AI. Does timing of transplantation of neural stem cells following spinal cord injury affect outcomes in an animal model?. J Spine Surg 2017 Dec;3(4):567-571.
    doi: 10.21037/jss.2017.10.06pmc: PMC5760427pubmed: 29354733google scholar: lookup

Citations

This article has been cited 19 times.
  1. Wang Y, Alexander M, Scott T, Cox DCT, Wellington A, Chan MKS, Wong MBF, Adalsteinsson O, Lakey JRT. Stem Cell Therapy for Aging Related Diseases and Joint Diseases in Companion Animals.. Animals (Basel) 2023 Jul 29;13(15).
    doi: 10.3390/ani13152457pubmed: 37570266google scholar: lookup
  2. Wang J, Wang L, Tian X, Luo L. N(6)-methyladenosine reader YTHDF1 regulates the proliferation and migration of airway smooth muscle cells through m(6)A/cyclin D1 in asthma.. PeerJ 2023;11:e14951.
    doi: 10.7717/peerj.14951pubmed: 36992945google scholar: lookup
  3. Mayet A, Zablotski Y, Roth SP, Brehm W, Troillet A. Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis.. Front Vet Sci 2023;10:1125695.
    doi: 10.3389/fvets.2023.1125695pubmed: 36908512google scholar: lookup
  4. Wang H, Fan M, An Y, He D. Molecular Mechanism of Long Noncoding RNA SNHG14 in Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells through the NEDD4L/FOXA2/PCP4 Axis.. Stem Cells Int 2023;2023:7545635.
    doi: 10.1155/2023/7545635pubmed: 36644009google scholar: lookup
  5. Even KM, Gaesser AM, Ciamillo SA, Linardi RL, Ortved KF. Comparing the immunomodulatory properties of equine BM-MSCs culture expanded in autologous platelet lysate, pooled platelet lysate, equine serum and fetal bovine serum supplemented culture media.. Front Vet Sci 2022;9:958724.
    doi: 10.3389/fvets.2022.958724pubmed: 36090170google scholar: lookup
  6. Soukup R, Gerner I, Gültekin S, Baik H, Oesterreicher J, Grillari J, Jenner F. Characterisation of Extracellular Vesicles from Equine Mesenchymal Stem Cells.. Int J Mol Sci 2022 May 23;23(10).
    doi: 10.3390/ijms23105858pubmed: 35628667google scholar: lookup
  7. Uberti B, Plaza A, Henríquez C. Pre-conditioning Strategies for Mesenchymal Stromal/Stem Cells in Inflammatory Conditions of Livestock Species.. Front Vet Sci 2022;9:806069.
    doi: 10.3389/fvets.2022.806069pubmed: 35372550google scholar: lookup
  8. Naumenko E, Guryanov I, Zakirova E, Fakhrullin R. Forskolin-Loaded Halloysite Nanotubes as Osteoconductive Additive for the Biopolymer Tissue Engineering Scaffolds.. Polymers (Basel) 2021 Nov 15;13(22).
    doi: 10.3390/polym13223949pubmed: 34833247google scholar: lookup
  9. Lee OJ, Koch TG. Steps Toward Standardized In Vitro Assessment of Immunomodulatory Equine Mesenchymal Stromal Cells Before Clinical Application.. Stem Cells Dev 2022 Jan;31(1-2):18-25.
    doi: 10.1089/scd.2021.0189pubmed: 34779250google scholar: lookup
  10. Bahroudi M, Bakhshi B, Soudi S, Najar-Peerayeh S. Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate.. Stem Cell Res Ther 2021 Nov 3;12(1):564.
    doi: 10.1186/s13287-021-02622-0pubmed: 34732259google scholar: lookup
  11. Cinat D, Coppes RP, Barazzuol L. DNA Damage-Induced Inflammatory Microenvironment and Adult Stem Cell Response.. Front Cell Dev Biol 2021;9:729136.
    doi: 10.3389/fcell.2021.729136pubmed: 34692684google scholar: lookup
  12. Zayed M, Adair S, Dhar M. Effects of Normal Synovial Fluid and Interferon Gamma on Chondrogenic Capability and Immunomodulatory Potential Respectively on Equine Mesenchymal Stem Cells.. Int J Mol Sci 2021 Jun 15;22(12).
    doi: 10.3390/ijms22126391pubmed: 34203758google scholar: lookup
  13. Pezzanite L, Chow L, Griffenhagen G, Dow S, Goodrich L. Impact of Three Different Serum Sources on Functional Properties of Equine Mesenchymal Stromal Cells.. Front Vet Sci 2021;8:634064.
    doi: 10.3389/fvets.2021.634064pubmed: 33996964google scholar: lookup
  14. Harman RM, Marx C, Van de Walle GR. Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy.. Front Cell Dev Biol 2021;9:654885.
    doi: 10.3389/fcell.2021.654885pubmed: 33869217google scholar: lookup
  15. Wang J, Jiao D, Huang X, Bai Y. Osteoclastic effects of mBMMSCs under compressive pressure during orthodontic tooth movement.. Stem Cell Res Ther 2021 Feb 25;12(1):148.
    doi: 10.1186/s13287-021-02220-0pubmed: 33632323google scholar: lookup
  16. Degroote RL, Deeg CA. Immunological Insights in Equine Recurrent Uveitis.. Front Immunol 2020;11:609855.
    doi: 10.3389/fimmu.2020.609855pubmed: 33488614google scholar: lookup
  17. Na L, Wang S, Liu T, Zhang L. Ultrashort Wave Combined with Human Umbilical Cord Mesenchymal Stem Cell (HUC-MSC) Transplantation Inhibits NLRP3 Inflammasome and Improves Spinal Cord Injury via MK2/TTP Signalling Pathway.. Biomed Res Int 2020;2020:3021750.
    doi: 10.1155/2020/3021750pubmed: 33376718google scholar: lookup
  18. Chu Y, Chen W, Peng W, Liu Y, Xu L, Zuo J, Zhou J, Zhang Y, Zhang N, Li J, Liu L, Yao K, Gao G, Wang X, Han R, Liu C, Li Y, Zhou H, Huang Y, Ye Y. Amnion-Derived Mesenchymal Stem Cell Exosomes-Mediated Autophagy Promotes the Survival of Trophoblasts Under Hypoxia Through mTOR Pathway by the Downregulation of EZH2.. Front Cell Dev Biol 2020;8:545852.
    doi: 10.3389/fcell.2020.545852pubmed: 33304896google scholar: lookup
  19. Li Y, Altemus J, Lightner AL. Mesenchymal stem cells and acellular products attenuate murine induced colitis.. Stem Cell Res Ther 2020 Nov 30;11(1):515.
    doi: 10.1186/s13287-020-02025-7pubmed: 33256827google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.